free counter

Developments in Gene Therapy for Ocular Diseases

Top Quote SAE Media Group reports: The Ophthalmic Drugs Conference will undoubtedly be concentrating on developments in Gene Therapy for Ocular Diseases. End Quote

  • (1888PressRelease) August 26, 2022 – The Ophthalmic drugs industry continues to expand year on year, having an ageing population there’s continual demand for advancements in ophthalmic treatments. This year’s Ophthalmic Drugs Conference could have a key concentrate on gene therapy and artificial intelligence with developments on the most recent drug pipelines and clinical trials.

    The conference will convene on 21 22 November 2022 in London, UK, this season attendees will hear from industry giants concerning the developments being manufactured in the ophthalmics and gene therapy field.

    Interested parties can register at – register by 30 September to save lots of 100.

    The 5th annual conference could have a far more in-depth discussion concerning the Developments in Gene Therapy for Ocular Diseases, with presentations and keynote speakers.

    Usage of Antisense Oligonucleotides for the treating Inherited Retinal Diseases

    Antisense oligonucleotides show much promise in Ph1/2 Clinical Trials in LCA10 and Ushers Syndrome

    Lessons learned from Ph 2/3 trial with Sepofarsen for LCA10

    Latest trial data from Interim Analyses for Ultevursen for Ushers syndrome and non-syndromic Retinitis Pigmentosa

    Led by: Aniz Girach, Chief Medical Officer, ProQR Therapeutics

    Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy

    LHON, a rare disease with high unmet medical need

    Development of Lumevoq Gene Therapy to take care of ND4 LHON patients Developments in Gene Therapy for Ocular Diseases Drug Delivery Regulatory pathways

    Key learnings from recent data

    Led by: Magali Taiel, Chief Medical Officer, Gensight Biologics

    Ocular Inflammation connected with Gene and Cell Therapy

    Immune privilege and the attention

    Inflammation and gene therapy

    Inflammation and cell-based therapy

    What things to search for.

    Led by: Virginia Calder, Professor of Ocular Immunology, University College London

    Strengthening the Therapeutic Landscape for Inherited Retinal Diseases Using Genome Editing with AAV Vectors & CRISPR/Cas9 Technologies

    Expanding on the clinical development of novel gene therapies including SPVN06

    The advantages of designing gene therapies to do something independently of the causative gene mutation

    An introduction to new clinical trials and future workings

    Led by: Daniel Chung, Chief Medical Officer, Sparing Vision

    For more information concerning the line up of the esteemed speakers for the conference also to download a free of charge brochure please visit

    For sponsorship enquiries contact Andrew Gibbons on +44 (0) 20 7827 6156 or email: agibbons ( @ ) smi-online dot co dot uk

    For media enquiries or perhaps a press pass contact Marketing, Simi Sapal on +44 (0) 20 7827 6162 or email ssapal ( @ ) smi-online dot co dot uk

    Ophthalmic Drugs

    21-22 November 2022

    London, UK


    Sponsor: The Technology Partnership | Celanese

    About SAE Media Group Conferences:

    SAE Media Group Conferences connects global communities with focused networking conferences. We offer our customers with solutions through industry knowledge and collaboration that allows our attendees to come back with their organisations better equipped to overcome their key business challenges. Our key events concentrate on Defence and Aerospace, Pharmaceutical and Medical. Every year we gather over 5,000 senior business professionals at our conferences.

    SAE Media Group (SMG), a subsidiary of SAE International, reports the most recent technology breakthroughs and design innovations to a worldwide audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals have to develop new and improved services and products.


Read More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker